With $78.5m in series B venture capital, Silverback Therapeutics Inc. will begin its first clinical trial later this year to determine whether its lead antibody-drug conjugate (ADC) SBT6050, which links a HER2-targeted antibody with a TLR8 agonist, will duplicate the company’s preclinical results that showed the ADC provided potent activation of myeloid cells and reprogrammed the tumor microenvironment.
Silverback has now raised more than $125m to date, including a series A extension that brought its initial funding round...